The Effect of Posttherapy 131 I SPECT / CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer

The objective of this study was to determine whether posttherapy 131I SPECT/CT changed the need for additional crosssectional imaging or modified the American Thyroid Association risk of recurrence classification. We performed planar imaging and SPECT/CT in a consecutive series of patients after 131I therapy. Methods: Planar imaging and SPECT/CT were performed on 148 consecutive patients with thyroid carcinoma (125 papillary, 2 follicular, 8 Hürthle cell, and 13 poorly differentiated) approximately 5 d after the therapeutic administration of 1,739–8,066 MBq (47–218 mCi) of 131I. The indication for treatment was postsurgical ablation (n 5 109) or recurrent or metastatic disease with rising thyroglobulin levels (n 5 39). SPECT/CT scans were obtained for all subjects for 1 bed position (38 cm), which included the neck and upper chest. Additional SPECT/CT scans of the abdomen or pelvis were acquired if suggestive findings were noted on planar images. All patients were treated in real time, according to the standard of care in our practice. At that time, clinical decisions regarding thyroid tumor classification were made by our multidisciplinary group based on all data, including operative findings, pathology, imaging, and thyroglobulin levels. In a retrospective analysis, planar and SPECT/CT images were interpreted independently, and sites of uptake were categorized as likely benign, malignant, or equivocal. An experienced thyroid endocrinologist used a combination of surgical histopathology and scan findings to determine whether additional cross-sectional imaging was required and determined if the imaging findings changed the patient’s risk category. Results: In 29 patients, 61 additional cross-sectional imaging studies were avoided using SPECT/ CT, compared with medical decision making based on the planar images alone. In 7 of 109 postsurgical patients, SPECT/CT findings changed the initial American Thyroid Association risk of recurrence classification. The sensitivity of planar imaging and SPECT/CT for identification of focal 131I uptake in the thyroid bed was similar in the postsurgical and recurrence cohorts. For metastatic disease in the neck, characterization of 131I uptake by SPECT/CT in the postsurgical group was significantly better than that by planar scanning (P , 0.01). Among the 109 postsurgical patients, the characterization of iodine uptake in the lung, liver, and bone was also more accurate using SPECT/ CT than planar scanning (P , 0.01). The CT portion of SPECT/CT demonstrated non–iodine-avid lesions in 32 of 148 patients. Conclusion: SPECT/CT data provided information that reduced the need for additional cross-sectional imaging in 29 patients (20%) and significantly altered the initial risk of recurrence estimates in 7 of 109 patients (6.4%), thereby altering patient management recommendations with regard to frequency and intensity of follow-up studies.

[1]  Y. Nishiyama,et al.  Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  R. Tuttle,et al.  Medical management of thyroid cancer: a risk adapted approach , 2008, Journal of surgical oncology.

[3]  S. Balachandran,et al.  Value of Thyroid Carcinoma Imaging After Therapeutic Doses of Radioiodine , 1981, Clinical nuclear medicine.

[4]  W. Bautz,et al.  Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation , 2008, Journal of Nuclear Medicine.

[5]  M. Beheshti,et al.  Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[7]  Giuseppe Madeddu,et al.  131I SPECT/CT in the Follow-up of Differentiated Thyroid Carcinoma: Incremental Value Versus Planar Imaging , 2009, Journal of Nuclear Medicine.

[8]  J. Němec,et al.  Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  K. Frey,et al.  Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. , 2008, AJR. American journal of roentgenology.

[10]  N. Heutte,et al.  Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[11]  H. Amthauer,et al.  Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma , 2004, Nuclear medicine communications.

[12]  W. Martin,et al.  Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Quan-Yong Luo,et al.  Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma , 2008, Journal of Nuclear Medicine.

[14]  R. Tuttle Risk-adapted management of thyroid cancer. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  Bruce Levin,et al.  The Analysis of Data from Matched Samples , 2004 .

[16]  S. Iwano,et al.  Diagnostic Whole-Body Scanning Before Radioiodine Therapy for Pulmonary Metastases of Differentiated Thyroid Cancer: Predictive Value and Recommendations , 2008, Clinical nuclear medicine.